Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series

Journal of Psychopharmacology
Bernardo Dell'ossoA Carlo Altamura

Abstract

Obsessive compulsive disorder (OCD) is a chronic disorder, currently recognized as one of the most common psychiatric disorder as well as one of the most disabling of all medical disorders. OCD is characterized by high rates of partial and/or absent response to standard, recommended treatments (serotonin reuptake inhibitors and psychotherapy). Recent investigation showed that Venlafaxine, a dual serotonin and norepinephrine reuptake inhibitor (SNRI), may be a valid alternative for some treatment-refractory patients. We present the cases of four OCD patients with comorbid mood or anxiety disorders, who were treated with serotonin reuptake inhibitors (SRIs) at adequate doses for at least 12 weeks, showing partial/no response. Patients were then switched to Duloxetine up to 120 mg/day and followed up for 12 weeks. Three out of four patients showed a Yale-Brown Obsessive Compulsive Scale(Y-BOCS) score reduction >or=35%. Duloxetine may be helpful in patients with treatment-resistant OCD, although larger and controlled studies are warranted to confirm this preliminary observation.

References

Nov 1, 1989·Archives of General Psychiatry·W K GoodmanD S Charney
Nov 1, 1989·Archives of General Psychiatry·W K GoodmanD S Charney
Dec 1, 2000·Depression and Anxiety·P H Roseboom, N H Kalin
Dec 26, 2001·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Jul 24, 2002·The International Journal of Neuropsychopharmacology·Stefano PallantiUNKNOWN International Treatment Refractory OCD Consortium
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Nov 19, 2003·Journal of Clinical Psychopharmacology·Damiaan DenysHerman G M Westenberg
Feb 10, 2004·CNS Spectrums·John H GreistUNKNOWN World Council of Anxiety
Nov 24, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Anders D WestanmoRobert Haight
May 4, 2006·The Journal of Clinical Psychiatry·Bernardo Dell'OssoEric Hollander
Sep 30, 2006·CNS Spectrums·Maria Alice de MathisEurípedes C Miguel

❮ Previous
Next ❯

Citations

Sep 21, 2011·Neuropsychiatric Disease and Treatment·Kelda H Walsh, Christopher J McDougle
Feb 3, 2009·Neuropsychiatric Disease and Treatment·Domenico De BerardisFilippo Maria Ferro
Apr 29, 2014·Expert Opinion on Pharmacotherapy·Mariana PizarroGabriela B de Menezes
Mar 26, 2013·Expert Opinion on Drug Metabolism & Toxicology·Mohammad SayyahMehdi Sayyah
Mar 3, 2015·Expert Opinion on Investigational Drugs·Giulio PerugiNunzio Bucci
Dec 20, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Murad Atmaca
Aug 18, 2010·Behavioural Brain Research·Sokichi HondaKazuo Takahama
Jun 19, 2009·Human Psychopharmacology·Paolo LeombruniSecondo Fassino
Mar 1, 2014·Journal of Pharmacy Practice·Gyula Bokor, Peter D Anderson
Jan 15, 2009·Journal of Clinical Psychopharmacology·Elias AboujaoudeNona Gamel
Aug 14, 2018·Current Neuropharmacology·Antonio Del CasaleMaurizio Pompili
Aug 23, 2020·Brain Sciences·Matteo VismaraBernardo Dell'Osso
Jun 12, 2009·CNS Spectrums·Martijn Figee, Damiaan Denys
Nov 5, 2016·Journal of Clinical Psychopharmacology·Arash MowlaSeyed Ali Dastgheib
Oct 25, 2008·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowJohann Vega
Jan 1, 2013·Trends in psychiatry and psychotherapy·Adelar Pedro FranzYgor Arzeno Ferrão

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.